Articles tagged with Tuberculosis
A study used next-generation sequencing to identify tuberculosis genes in a 19th-century skeleton, revealing a historic strain of the disease. The technology saved time and accurately identified DNA, paving the way for further research into the disease's evolution.
A study found that linezolid, an antibiotic used to treat severe bacterial infections, proved largely effective in treating extensively drug-resistant tuberculosis (XDR-TB) when added to ongoing treatment regimens. However, 82% of patients experienced significant adverse events that may have been related to the drug.
An observational study found that delamanid can improve outcomes and reduce mortality among MDR-TB and XDR-TB patients when taken for at least 6 months. The treatment resulted in a 74.5% favourable outcome rate, significantly higher than the 55% rate for shorter treatment periods.
Large donors are forcing the World Health Organization to re-evaluate its priorities and agenda-setting process. This shift towards 'multi-bi financing' has raised concerns about the control of international agencies by participating governments.
Research from the University of Copenhagen suggests that dividing campaigns into combating non-communicable or communicable diseases is ineffective and expensive. Integrated health programmes focusing on common risk factors like poor nutrition can effectively combat diseases such as diabetes and tuberculosis.
Researchers found pyridomycin selectively kills Mycobacterium tuberculosis, including strains resistant to front-line drug isoniazid. The natural antibiotic targets the InhA enzyme, which is essential for bacterial cell wall production.
Researchers have found that an off-patent anti-inflammatory drug, oxyphenbutazone, can kill both replicating and non-replicating drug-resistant tuberculosis in laboratory tests. The effective drug may offer a potential new therapy for the over 500,000 people worldwide whose TB has become resistant to standard drug treatments.
A provocative essay in NEJM calls for redoubling efforts to combat TB, highlighting global health inequity and inadequate treatment. The authors advocate for adopting a zero-TB death goal, rapid diagnosis, and infection control measures to stem the pandemic.
Researchers used whole-genome sequencing to track TB outbreak, identifying origin and movement of pathogens, key persons and behaviors that contributed to spread. The study found location-based transmission is crucial for outbreak management and informs public health policy and practice.
Researchers found that high doses of vitamin D, given with antibiotic treatment, accelerate recovery in TB patients by dampening down the body's inflammatory response. Vitamin D supplementation may also benefit patients recovering from pneumonia.
A new study reveals alarmingly high levels of extensively drug-resistant tuberculosis worldwide, with nearly 44% of patients showing resistance to at least one second-line drug. The highest prevalence was seen in South Korea and Russia, with the risk of XDR disease quadrupled in previously treated patients.
Researchers propose a novel vaccine strategy using lipidated-promiscuous-peptide vaccines to overcome limitations of existing BCG vaccine, which fails to prevent disease in adults, especially in endemic regions. This new approach has shown promise in animal models and is being tested in human clinical trials.
A large study found that using certain drugs, four or more effective drugs, and a duration of 7-8.5 months can lead to successful patient outcomes in MDR-TB treatment. However, the findings should be interpreted with caution due to limitations in the methods and data.
David M. Tobin has made significant contributions to TB meningitis treatment and is developing new approaches to tackle drug-resistant TB. His work uses zebrafish models to probe host genetic determinants of susceptibility to mycobacterial infection.
The Iowa State researchers discovered the structure of a regulator that controls the expression of a multidrug efflux pump in Mycobacterium tuberculosis. This finding is crucial for understanding how tuberculosis bacteria develop drug resistance, providing a starting point for developing new strategies to combat the disease.
Dartmouth medical research has made a breakthrough in developing a new tuberculosis vaccine, DAR-901. The vaccine, produced by growing bacteria related to TB on agar plates and then inactivating them with heat, has shown a statistically significant reduction of 39% in the rate of tuberculosis among HIV-infected patients.
High rates of HIV, hepatitis C, and tuberculosis have been found in homeless populations globally, with rates up to 46 times higher in the US than in the general population. Infections can lead to community spread, malnutrition, and increased healthcare use.
Resistant tuberculosis is a serious threat to world health, with 'multiresistant' cases now making up 1 in 3 new TB cases. A new approach using vital staining with fluorescein diacetate detects resistant bacilli early, allowing for timely treatment and preventing further spread.
A mobile HIV-testing clinic integrated with active tuberculosis case finding in underserviced areas of Cape Town demonstrated high feasibility, yield, and treatment success. The study found that the service was well-received by HIV-negative individuals with symptoms suggestive of TB, as well as all HIV-positive individuals.
A new analysis by UCSF/SFGH researchers suggests the recommended dose adjustment of efavirenz may not be necessary, especially in non-Caucasian populations. The study found no significant difference in efavirenz levels between patients weighing more than 50 kg and those weighing less than 50 kg.
A new combination of drugs to treat tuberculosis shows promise, killing over 99% of patients' TB bacteria within two weeks. The treatment could also be used for patients infected with drug-resistant forms of the disease.
A novel approach to discover the first new tuberculosis (TB) combination drug regimen has cleared a major hurdle with a Phase II clinical trial finding it could kill more than 99 percent of patients' TB bacteria within two weeks. The results add to a growing body of evidence that this regimen could reduce treatment by more than a year ...
Researchers found that inhibiting a key immune response early on can shorten TB treatment time and prevent relapse. In a study, mice treated with standard TB medication plus a TNF-alpha inhibitor had a significantly lower bacterial burden than those receiving only the standard treatment.
Seven pharmaceutical companies, including Abbott, AstraZeneca, and Sanofi, have joined forces with four research institutions to accelerate the development of new tuberculosis (TB) drugs. The TB Drug Accelerator aims to shorten treatment regimens from six months to one month, reducing mortality rates and combating drug resistance.
Researchers developed a new swab technique that can spot tuberculosis in non-human primates with no outward signs of disease. The method has been successfully tested on Asian monkey populations, revealing a significant prevalence rate and potential for primate-to-primate transmission.
A nationwide survey in China reveals one in 10 newly diagnosed TB patients are infected with drug-resistant strains, with over 5,000 cases annually. Experts emphasize the need for rapid testing to determine drug resistance and developing new combination therapies to combat multidrug-resistant tuberculosis.
Researchers at Albert Einstein College of Medicine have been awarded a $5.9 million NIH grant to develop a new TB vaccine against multi-drug resistant and extensively drug-resistant strains. The approach is based on genetically altered Mycobacterium smegmatis, which can generate a robust immune response in animals.
Researchers found that reducing TB infections in geographic hotspots can significantly reduce citywide transmission rates by up to 29% over 50 years. Controlling these hotspots may have a similar impact on long-term, community-wide TB incidence as achieving the same targets in the remaining population.
A parasitic flatworm called Fasciola hepatica hinders the diagnosis of bovine tuberculosis (TB) in cattle by reducing the sensitivity of skin tests. This study found that liver fluke infection can create false negatives for TB, allowing infected cattle to continue transmitting the disease.
A microfluidic chip test has been developed to detect latent tuberculosis, promising to be cheaper and faster than current methods. The test uses a novel approach to detect interferon-gamma in blood samples, triggering an electrical signal for diagnosis.
A study of over 3,000 dairy herds in England and Wales found that liver fluke infection reduces the sensitivity of skin tests used to diagnose bovine TB. This means infected cattle may not be identified by current surveillance schemes, contributing to the disease's spread.
A new study found that active tuberculosis is an independent predictor of lung cancer death in the elderly. The research analyzed data from 61,239 subjects aged 65 years or older and found a significant association between tuberculosis and lung cancer mortality.
Researchers developed a simple and inexpensive method to detect more cases of tuberculosis using vacuum filtering a sputum sample through a small filter. The new technique detected 89% of cases in Brazil, compared to 60% detection with the traditional method.
A Michigan State University researcher has developed a synthetic biosensor that glows green in response to conditions mimicking human tuberculosis infection. The goal is to find new treatments for chronic TB and multidrug-resistant TB.
Funding for non-custodial alternatives, community service, and legal representation are essential to reduce overcrowding and HIV/TB transmission. African governments have a responsibility to address life-threatening prison conditions contrary to international law.
Researchers have identified biosignatures for tuberculosis and sarcoidosis, but a single signature is insufficient to distinguish between the two diseases. A combination of markers is required to accurately diagnose a specific disease, enabling doctors to distinguish between different diseases with similar clinical appearances.
A new diagnostic tool for tuberculosis (TB) offers improved accuracy and speed, allowing for faster treatment. The Xpert MTB/RIF assay is a fully automated test that determines TB infection and multidrug-resistant strain in under an hour.
The European Respiratory Society and ECDC introduce new EU Standards for Tuberculosis Care to bridge gaps in TB case management. The guidelines include recommendations such as drug susceptibility testing and proper isolation protocols to combat multidrug-resistant TB cases.
A two-drug combination of meropenem and clavulanate has been shown to effectively treat forms of TB that are resistant to other antibiotics. The treatment offers new hope for dealing with drug-resistant TB, which is a major public health concern globally.
A genetic study in Vietnam aims to find out why only one in ten people carrying the tuberculosis bacterium become sick. The research, led by Australian scientist Dr Greg Fox, seeks to identify genes that increase TB risk.
Scientists have made significant progress in building knowledge and infrastructure to develop novel tuberculosis vaccine candidates. The next decade of research will focus on investigating remaining fundamental questions and leveraging recent innovations in systems biology, genomics, and bioinformatics.
Researchers and experts call for intensified global collaboration to develop effective new vaccines against tuberculosis. The blueprint outlines a path forward to create more effective, safe vaccines that can protect people from childhood TB, pulmonary TB, and latent TB.
Researcher Russell Chesney hypothesizes that 18th century London's crowded living conditions, poor diets, and low sunlight exposure contributed to high rates of rickets and tuberculosis in children like Tiny Tim. Improved nutrition, vitamin D from sunlight and cod liver oil could have prevented the boy's fatal condition
The Bill & Melinda Gates Foundation grants Aeras up to $220 million to develop safe and effective TB vaccines amid rising drug-resistant strains. The funding aims to accelerate global efforts to eliminate the airborne threat.
Researchers at the University of Pittsburgh have developed a novel way to culture tuberculosis bacteria, which could lead to new treatments and insights into its extraordinary resilience against environmental stresses. The bacteria's ability to form biofilms is thought to be a key factor in its resistance to treatment.
The Forsyth Institute is developing a low-cost diagnostic tool for tuberculosis (TB), which can quickly and accurately diagnose active TB cases in developing countries. The project focuses on identifying and validating seven proteins of Mycobacterium tuberculosis as biomarkers of active disease.
The University of Louisville will receive a $576,800 grant to develop a low-cost, simple test for diagnosing tuberculosis (TB) in developing countries. Researchers aim to identify and validate TB biomarkers using a disposable sampling plate and breath test.
SomaLogic will develop a low-cost diagnostic tool using its proteomic technology to detect TB biomarkers. The grant aims to improve identification of active TB cases in developing countries.
The study found that 10% of TB patients received less than the recommended four drugs, while almost 34% of HIV-positive patients were not satisfactorily managed. The research highlights the need to increase awareness, training, and resource allocation to prevent drug-resistant TB cases.
Researchers found a gene, LTA4H, that influences inflammation to TB infection, predicting drug therapy effectiveness. This discovery suggests tailoring treatment based on patients' genetic sequences could improve patient outcomes.
Researchers found that a single 'Goldilocks' gene, LTA4H, regulates the immune response to TB. Variations in this gene lead to excessive or insufficient inflammation, which can affect treatment response. The study suggests personalized medicine could improve TB treatment outcomes.
Research finds a significant association between pulmonary TB and EGFR mutations in lung cancer patients. The study reveals that tumors with these mutations respond well to targeted therapies, offering new hope for treatment.
Researchers at Michigan State University used advanced DNA testing to confirm the presence of brucellosis in skeletal remains from medieval Albania, suggesting the disease was endemic in the region since the Middle Ages. The findings provide valuable insights into the history of infectious diseases and their impact on human health.
Researchers found that multidrug-resistant tuberculosis is more likely caused by speedy drug metabolism rather than inconsistent doses. The study suggests monitoring patients' drug concentrations during treatment may be as important as compliance with therapy.
A University of Texas at Austin chemist has received a $1.6 million grant to develop a simple, paper-based test for detecting drug-resistant tuberculosis. The goal is to create a real-time test that can be used in resource-poor communities without refrigeration.
Researchers discovered that mycobacterial cell growth patterns determine their susceptibility to antibiotics, providing new avenues for targeted treatment. The findings could lead to more effective treatments for the deadly disease, which kills over 1.5 million people annually.
A study found that commercially-available tests for latent TB infection have high false-positive rates in low-prevalence populations, with 77% of subjects having positive results with only one test. The findings suggest that risk stratification may increase the predictive value and reduce false positives.
A UK-wide cohort study found a significant increase in tuberculosis (TB) diagnoses among postpartum women, with a higher risk of TB in the six months following pregnancy. The study suggests that targeted screening of pregnant and post-partum women in high-risk groups may be necessary to prevent poorer outcomes.
A new TB vaccine candidate has entered Phase I clinical trials in South Africa to assess its safety and immunogenicity in latently infected adults. The vaccine, SSI H56-IC31, has shown efficacy in pre-clinical studies and holds promise for preventing active TB disease in a vast population.
Researchers developed a new TB vaccine H56 that reduces clinical disease and prevents reactivation of latent infection when combined with BCG, a current but ineffective vaccine. This breakthrough could lead to improved protection against TB.